Remdesivir "is now the first and only approved covid-19 treatment in the U.S."
After being one of the frontrunners in finding a viable COVID-19 vaccine, Gilead passed a new milestone.
The continuous promising results made the U.S. Food and Drug Administration approve Gilead's antiviral Remdesivir. It is the first drug of its kind to receive formal clearance to treat COVID-19 infected patients.
The medicine’s approval comes after earlier this year it was granted an emergency use authorization to be administrated to hospitalized patients. It will be sold under the name of Veklury. Moreover, President Trump underwent the treatment when he was found positive for COVID-19 infection. However, according to a report from the World Health Organization, Remdesivir didn't reduce the death toll caused by the virus.
"Veklury is now the first and only approved Covid-19 treatment in the United States," read Gilead's statement. Moreover, if in the beginning, the drug was shot on supply, now, the manufacturing capacity has expanded.
Following the report, Gilead's stock price gained 0.76%. In today's pre-market trading, it went up more than 5.50%.
Sources: thestreet.com, Bloomberg.com